A Phase II Study of Ipilimumab in Combination With Carboplatin and Paclitaxel in Patients With Unresectable Stage III or Stage IV Melanoma
Phase of Trial: Phase II
Latest Information Update: 07 Jun 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Carboplatin; Paclitaxel
- Indications Malignant melanoma
- Focus Adverse reactions
- 07 Jun 2019 Status changed from active, no longer recruiting to completed as per results presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 28 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.